adl018

ADL018 is a humanized monoclonal antibody developed as a biosimilar to omalizumab (Xolair). It functions by inhibiting the binding of immunoglobulin E (IgE) to the high-affinity IgE receptor (FcεRI) on mast cells and basophils, thereby preventing allergic inflammatory responses. ADL018 is being developed for indications including chronic spontaneous urticaria (CSU), moderate to severe persistent asthma, and chronic rhinosinusitis with nasal polyps. The drug matches the pharmaceutical form, dosage strength, route of administration, and dosing regimen of US/EU-approved omalizumab. Clinical studies have demonstrated pharmacokinetic similarity between ADL018 and reference omalizumab[1][2][3][4][5][8].

Other names

omalizumab biosimilarXolair biosimilar